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Abstract
Summary The Global Longitudinal study of Osteoporosis
in Women (GLOW) is a prospective cohort study involving
723 physicians and 60,393 women subjects ≥55 years. The
data will provide insights into the management of fracture
risk in older women over 5 years, patient experience with
prevention and treatment, and distribution of risk among
older women on an international basis.
Introduction Data from cohort studies describing the
distribution of osteoporosis-related fractures and risk
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Methods The GLOW is a prospective, multinational,
observational cohort study. Practices typical of each region
were identified through primary care networks organized
for administrative, research, or educational purposes.
Noninstitutionalized patients visiting each practice within
the previous 2 years were eligible. Self-administered
questionnaires were mailed, with 2:1 oversampling of
women ≥65 years. Follow-up questionnaires will be sent
at 12-month intervals for 5 years.
Results A total of 723 physicians at 17 sites in ten countries
agreed to participate. Baseline surveys were mailed (Octo-
ber 2006 to February 2008) to 140,416 subjects. After the
exclusion of 3,265 women who were ineligible or had died,
60,393 agreed to participate.
Conclusions GLOW will provide contemporary informa-
tion on patterns of management of fracture risk in older
women over a 5-year period. The collection of data in a
similar manner in ten countries will permit comparisons of
patient experience with prevention and treatment and
provide insights into the distribution of risk among older
women on an international basis.
Keywords Fracture.Osteoporosis.Prevention.
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Introduction
A number of cohort studies have detailed the distribution of
osteoporosis-related fractures and their accompanying risk
factors in different regions of the world [1–18]. As these
studies varied in their objectives and methods of data
collection, the comparability of the information obtained
may be limited. Furthermore, existing reports do not
compare regional differences in patterns of patient manage-
ment and outcomes of fracture.
The Global Longitudinal study of Osteoporosis in Women
(GLOW) is an observational longitudinal study designed to
improve understanding of international patterns of suscepti-
bility, recognition, management, and outcomes of care in
women aged 55 years and older at risk for fragility fractures.
The aim of the GLOW study is to collect uniform data to: (1)
describe the distribution of risk factors for osteoporosis-
related fracture; (2) apply published fracture risk assessment
tools in a population of older women; (3) identify differences
in physician patterns of diagnosis and management of
osteoporosis (e.g., how health care providers are identifying
individuals for treatment; characteristics of women being
treated); (4) characterize factors that influence patient persis-
tence with treatment, including patient characteristics, aware-
ness of fracture risk and comorbid conditions; (5) assess the
real-world effectiveness of care on the incidence of fracture;
and (6) evaluate the cost effectiveness of interventions for the
prevention and management of osteoporosis from the per-
spective of the health care provider.
Study design
Study site selection
GLOW is being conducted in physician practices in 17
study sites in ten countries (Australia, Belgium, Canada,
France, Germany, Italy, Netherlands, Spain, UK, and USA)
in Australia, Europe, and North America. These sites are
located in major population centers (Table 1). A Scientific
Advisory Board comprising investigators at each of the 17
sites was constituted to provide scientific oversight and
study management. These individuals are independent
university-based investigators with content expertise in
osteoporosis, who represent the disciplines of endocrinol-
ogy, rheumatology, geriatric medicine, and epidemiology.
These sites were selected based on the ability of the local
investigators to consistently administer the survey method-
ology, on the availability of a wide spectrum of osteopo-
rosis treatment options and bone densitometry, and the
existence of prior studies in those regions, which would
provide data for comparison with the GLOW sample.
Practical considerations concerning the number of survey
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1108 Osteoporos Int (2009) 20:1107–1116translations and number of countries in which the survey
process could be supervised restricted the number of sites to
those chosen for this study.
Physician sample selection
Practices typical of each region were recruited through
primary care networks organized for administrative, re-
search, or educational purposes or by identifying all
physicians in a geographic area. Physician networks
included regional health-system-owned or managed practi-
ces, health maintenance organizations, independent practice
associations, and other primary care practice networks.
Networks established for the purpose of general medical
research were used only if they were not established
exclusively for osteoporosis research and did not consist
of physicians whose primary focus was academic.
Primary care physicians were defined as physicians who
spent the majority of their time providing primary health
care to patients. Depending on the country in which the
study site was located, this included internists, family
practitioners, and general practitioners who provide primary
care. If the physician network or study area included more
eligible physicians than were required to recruit a sufficient
number of patients, a random sample of those physicians
within the network or study was invited.
Each physician completed a standardized form that
collected data on their demographics and practice character-
istics (Table 2).
Patient selection
Each physician practice provided a list of the names and
addresses of women aged 55 years and older who had
consulted their physician in the past 24 months. These lists
comprised the sampling frame. Sampling was stratified by
age to ensure that two thirds of the women surveyed were
65 years of age and older. In each practice, we recruited
from all eligible women 65 and over and a random sample
of half that number under age 65 years. Sample size
estimates were generated to detect a 30% difference in 5-
year fracture incidence between treated and untreated
patients with a power of 80%. On this basis, a sample of
approximately 3,000 patients was sought at each site.
Patients were excluded if they were unable to complete
the study survey due to cognitive impairment, language
barriers, or institutionalization or were too ill.
Instrument development
Questionnaires were designed to be self-administered and
cover the domains outlined in Table 3. Where possible,
items from published validated instruments were used,
including the National Health and Nutrition Examination
Survey (NHANES) [19], EuroQol (EQ-5D) [20], and SF-36
[21] (physical function component). Questions that had not
Country, state/province and postal code
Demographics: sex and age
Primary and secondary specialties
Percentage of time devoted to primary and secondary specialties
Number of patients in the physician’s panel
Practice type: solo, single specialty group, multispecialty group, size of group
Availability of on-site bone mineral density testing
Table 2 Physician data
Table 1 Study sites and number of patients enrolled per site
Region Site Physicians Patients
Australia Sydney 51 (GP) 2,904
Canada Hamilton,
Ontario
35 (GP) 3,985
Europe Belgium Leuven 31 (GP) 3,692
France Lyon 52 (GP) 3,366
Paris 45 (GP) 1,714
Germany Essen 39 (GP) 3,465
Italy Verona 44 (GP) 3,252
Netherlands Amsterdam 14 (GP) 2,856
Spain Barcelona 62 (GP) 2,910
UK Southampton 52 (GP) 4,079
USA Birmingham,
Alabama
9 (FP) 5,061
33 (IM)
Cincinnati,
Ohio
8 (FP) 3,128
14 (IM)
Los Angeles,
California
20 (FP) 3,102
16 (IM)
Pittsburgh,
Pennsylvania
5 (FP) 4,233
15 (IM)
Rockland County,
New York
1 (FP) 3,500
71 (IM)
Seattle,
Washington
55 (FP) 4,055
7 (IM)
Worcester,
Massachusetts
5 (FP) 5,091
39 (IM)
GP general practice, FP family practice, IM internal medicine
Osteoporos Int (2009) 20:1107–1116 1109been used previously were tested cognitively in the context
of the complete questionnaire in a sample of women in the
study age group. The complete baseline questionnaire was
also pilot-tested before being finalized to gauge subject
comprehension and completion time. Questionnaires were
translated into five languages (French, Spanish, German,
Italian, and Dutch) in addition to English by the University
of Massachusetts-Amherst Translation Center. Where items
from existing questionnaires had been translated previously,
these items were incorporated directly. Translations were
reviewed by study coordinators at each site for accuracy
and consistency with local idiom. Because NHANES is
administered to a representative sample of US residents, it
was possible to compare responses to items that were
similar in the GLOW survey to assess the similarity of the
populations. Data from NHANES conducted in 2005 and
2006 were used for this purpose.
Survey administration
Eachstudysiteobtainedethicscommitteeapprovaltoconduct
the study in the specific location. Baseline questionnaires
along with invitations to participate in the study signed by the
local principal investigator were mailed to all potential
patients. Nonrespondents were followed up with a series of
postcard reminders, second questionnaires, and telephone
interviews, as outlined in Fig. 1. Women who responded will
be resurveyed annually for the next 4 years. In addition to
repeating questions about medications, quality of life, and
functional status, the follow-up surveys will include ques-
tions about persistence with medication, reasons for non-
adherence, and detail about fracture-associated treatment.
Patient identity is safeguarded by the local study
coordinator, who assigns an ID number to each participant
at enrollment and maintains the site’s participant list locally.
The names of patients are stored separately from study data
transmitted to the central coordinating center (Center for
Outcomes Research at the University of Massachusetts
Medical School). Thus, unique patient identifiers are
confidential to the investigators at each study site.
The process for entering, verifying, and managing
survey data is uniform across all study sites. Completed
questionnaires are sent to the central coordinating center,
where they are scanned electronically, and data fields are
audited visually by a person trained to process the forms.
The data entry software is designed to detect out-of-range
values, inconsistencies, and omissions and to document any
resolutions. Scanned data are entered into a database stored
on a secured password-protected computer. As a quality
control measure, each study site maintains an administrative
database that tracks surveys mailed and received, and
scanned surveys are checked against these databases. Twice
yearly meetings are held with study coordinators from each
of the study sites to review survey administration and
ensure uniformity of the process. For study sites using
telephone follow-up in addition to mail, a standard
telephone script is used and reviewed with each site to
ensure consistency of telephone survey administration.
Results
A total of 723 physicians agreed to participate in the
GLOW study and supplied practice lists. The number of
physicians ranged from 14 to 72 per site (median 40). In the
US, 298 participating physicians comprised 103 family
physicians and 195 internal medicine physicians. All
Canadian, Australian, and European participants were
general practitioners.
Baseline surveys were mailed between October 2006 and
February 2008 to 140,416 potential subjects (Fig. 1). After
Table 3 Baseline questionnaire items
Item Questions
Patient characteristics
and risk factors
Age; race (US only); current height;
height at age 25; current weight; height
loss in past year; education level; years
since last menstrual period; maternal
history of osteoporosis; parental hip
fracture; falls in past 12 months; arms
needed to assist in standing from a
chair; fractures since age 45; smoking
status; alcohol use
Perception about fracture
risk and osteoporosis
Level of concern about osteoporosis;
talked with doctor about osteoporosis;
patient told she has osteoporosis or
osteopenia; talked with doctor about
fall prevention; ever had bone density
test; perception of fracture risk;
perception of osteoporosis risk
Medication use (currently
taking or ever taken)
Prescription bone medications (country
specific); calcium; vitamin D;
estrogen or hormone replacement;
cortisone or prednisone; anastrozole;
exemestane; letrozole; tamoxifen
Comorbidities
(ever diagnosed)
Asthma; chronic bronchitis or
emphysema; osteoarthritis; rheumatoid
arthritis; stroke; ulcerative colitis or
Crohn’s disease; celiac disease;
Parkinson’s disease; multiple sclerosis;
cancer; type 1 diabetes; hypertension;
heart disease; high cholesterol
Health care use and access Patient has health coverage (country
specific); nights of hospitalization in
past year; visits to doctor in past year
Physical activity Number ofdayswhen walked≥20minin
past 30days;level ofactivity compared
with other women of the same age.
Physical function and
quality of life
SF-36 physical function component;
EQ-5D
1110 Osteoporos Int (2009) 20:1107–1116the exclusion of 3,265 patients who were either ineligible or
had died, 60,393 women agreed to participate. The median
response rate among the 17 study sites was 62% (range
15–75); 76% of the study sites had a response rate of 50%
or greater. Two sites experienced notably lower response
rates than were typical. In both Italy and Spain, the lower
response to mailed surveys had been anticipated based on
prior experience with mail surveys in those regions;
accordingly, higher numbers of surveys were sent to
potential participants in order to collect the targeted 3,000
responses.
The characteristics of the 60,393 women who partici-
pated in GLOW are displayed in Table 4. The mean age
was 69 years and mean weight 148 lb (67.2 kg). Among
characteristics known to place women at increased risk of
fragility fracture, weight <125 lb (57 kg) was present in
16%, history of maternal hip fracture in 13%, and personal
history of a fracture of the wrist, spine, or hip in 12%.
Twenty-two percent had been told by a doctor or health
professional that they had osteoporosis; 11% reported
asthma, and 11% rheumatoid arthritis; 23% of women said
their health status was “fair” or “poor.”
Comparisons of demographic characteristics and risk
factors for the US GLOW subjects and for women aged 55
and older sampled in the NHANES study (2005 to 2006)
are also displayed in Table 4. Although the mean ages for
the two groups were similar, women in the GLOW sample
had received a higher level of education, were more often
white, and had better self-reported health than women in
the NHANES study. History of wrist fracture was also
somewhat lower in the GLOW population than in the
NHANES population. However, many of the risk factors
were similar among the two samples, for example low
weight, osteoporosis diagnosis, fracture of the spine or hip,
and maternal fracture. The prevalence of common comor-
bid conditions, such as hypertension, high cholesterol, and
asthma, was also similar.
When women were asked how concerned they were
about osteoporosis, 54% expressed “some” concern and
25% said they were “very concerned” about the condition
(Table 5). Overall, 43% said they had spoken with their
doctor about osteoporosis testing, treatment, or prevention
in the past 12 months. Twenty-one percent of women
reported having been told by their doctor or health provider
that they had osteoporosis; 19% said they were told they
had osteopenia. When asked to rate their own risk of
getting osteoporosis compared with women their own age,
33% rated their risk as lower and 19% as higher.
Discussion
GLOW is designed to provide an international perspective
on fracture risk in women, patient management practices,
patient awareness, physical and emotional function follow-
ing fracture, application of risk assessment models, and
functional outcomes following fracture. Previous cohort
studies of osteoporosis were designed primarily to identify
factors associated with fracture incidence and document the
distribution of low bone mineral density and its association
with fracture risk. These efforts have been limited to
specific regions or areas. GLOW will provide the first
description of patterns of risk from an international
perspective. Further, the data from GLOW will be used to
assess not only fracture risk and incidence, but will identify
patient concern and awareness and clinical management at
a time when significant efforts have been made to
implement treatment guidelines and educate patients about
osteoporosis and fracture risk. In these baseline results, a
Primary care practices 
(N=723)
Women visiting practice within 
previous 2 years (age-weighted 
random sample)* 
Survey mailing list 
(N=140,416) 
Survey sample: Baseline 
questionnaire + invitation to 
participate sent to eligible women 
aged 55 years and over (N=137,151) 
Ineligible or deceased 
(N=3265) 
Respondents followed up 
annually for 4 years 
Respondents: patient study 
population 
(N=60,393) 
Non-respondents sent 
reminder  
Second questionnaire mailed 
to non-respondents 
7–10 days later 
3–4 weeks later 
All sites except Cincinnati, 
New York, Essen, and 
Southampton, women who 
had not returned a 
questionnaire or opted out 
were offered the opportunity 
to complete it over the phone. 
5–6 weeks later 
Fig. 1 Recruitment/enrollment flow chart. Asterisk, age-stratified
sampling not feasible in Sydney, Paris, or Lyon
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and older, indicated having discussed osteoporosis with
their physician in the past year, yet 79% of women in the
study were somewhat or very concerned about osteoporo-
sis. Future analyses of GLOW data will examine the link
between perceived risk, concern, and physician encounters
on treatment risk of fracture and quality of life.
Prior studies have reported undertreatment and under-
diagnosis of osteoporosis [22]. However, since these studies
were conducted, many new therapies have become more
widely used than in the past. GLOW will report on
contemporary treatment prevalence according to fracture
risk and self-reported diagnosis of osteoporosis at a time
when a wider range of patient management options have
been generally accepted and are available
Previously collected risk factor data form the basis for
risk-scoring algorithms designed to predict fracture risk and
aid physicians in targeting treatment to those most in need
[23–26]. GLOW will update data on these factors and allow
the calculation of patterns of international fracture risk.
Because the data will be gathered in a consistent manner,
confidence will be increased that the variations seen in the
distribution of risk factors between regions is due to
differences in the populations rather than in the methods
of data collection.
Table 4 Characteristics of women participating in GLOW, US women participating in GLOW, and NHANES women aged 55 years and older for
2005 to 2006
All GLOW women US GLOW women
a NHANES women (2005–2006)
(n=60,393) (n=28,170)
Mean age, years (SE) 69 (0.04) 69 (0.05) 68 (0.32)
Mean weight, lb (SE) 148 (0.3) 159 (0.2) 163 (1.0)
%
Weight<125 lb (57 kg) 16 15 16
Broken wrist
b 8.7 7.4 9.8
c
Broken spine
b 2.3 1.9 1.6
c
Broken hip
b 1.9 2.1 2.1
c
Maternal hip fracture 13 13 11
c
Ever diagnosed with
Asthma 11 14 12
Chronic bronchitis or emphysema 9 9.1 12
High cholesterol 50 57 54
Hypertension 51 56 56
Osteoporosis 22 20 24
c
Osteoarthritis or degenerative joint disease 40 32 24
Rheumatoid arthritis 11 9.4 8.5
General health “fair or poor” 23 15 22
Non-Hispanic white NA 86 80
Education level
Less than high school NA 7.4 23
High school NA 26 30
More than high school NA 67 47
NA not available, SE standard error
aFrequencies are age-standardized to the whole GLOW population
bFractures are since age 45 in GLOW, “ever” in NHANES
cData are from NHANES 2003 to 2004 (n=1,108), the latest year with these data available
Table 5 Subjects’ awareness of osteoporosis
Percent
Concern about osteoporosis
Very concerned 25
Somewhat concerned 54
Talked with their doctor about osteoporosis 43
Doctor told subject she had osteoporosis 21
Doctor told subject she had osteopenia 19
Self-rated risk of osteoporosis
Lower 33
Higher 19
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patient interactions including discussion of osteoporosis,
advice concerning falls, bone mineral density screening,
diagnosis of osteoporosis, and pharmacological treatments.
Regional and international comparisons of diagnosis and
treatment patterns will be possible, with adjustment for
region- and country-specific characteristics, such as the
availability of health insurance, reimbursement for pre-
scriptions, and treatment protocols. A number of items that
assess subjects’ physical and emotional status have also
been incorporated in the questionnaire. These include the
mobility and vitality scales from SF-36 and the five
subscales of the EQ-5D. Such measures will enable
comparisons of functional outcomes for women who suffer
various types of incident fractures in differing geographic
regions over time.
Whereas most studies of patient persistence focus on a
single drug, GLOW will include the full range of currently
available pharmacological treatments for osteoporosis
(alendronate, calcitonin, estrogen, etidronate, ibandronate,
pamidronate, parathyroid hormone [1–84], raloxifene,
risedronate, strontium ranelate, teriparatide, tibolone, and
zoledronate). We will also be able to include any newly
available osteoporosis medications in the questionnaire.
The study will also examine the reasons why patients stop
and switch medications.
GLOW data will allow assessment of the effectiveness
of treatment on the incidence of fracture in a “real-world”
setting. In contrast to randomized clinical trials, GLOW did
not exclude women who had previously been diagnosed
with osteoporosis or treated with bone drugs. Consequently,
analysis of the treated population will include those women
who stop or switch medications, as well as those who have
a high degree of persistence. Adjustment will be possible
for potential confounding of the relationship between
treatment and fracture using fracture risk factors and risk
scores. While the study is not designed to evaluate the
effectiveness of any single bone drug, it will allow
comparison of fracture rates among treated and untreated
patients across all classes of interventions. Such head-to-
head comparisons have not been evaluated in randomized
controlled trials.
Analysis will also be carried out to estimate the relative
cost effectiveness of various classes of interventions used in
the management of fractures, using the usual principles set
out for cost-effectiveness analysis [27–29]. An economic
model based on the epidemiological evidence of treatment
outcomes recorded in GLOW will be constructed [30].
GLOW is a practice-based rather than a population-
based study and is subject therefore to biases in both the
selection of physicians and the sampling and recruitment of
patients. Practical considerations limited our sample selec-
tion to women from 17 study locations in ten countries. An
expanded sample that included a broader representation of
racial and ethnic groups was not pursued because of the
complexity of administering a recruitment methodology
involving oversampling of particular racial and ethnic
groups in ten different countries, where the definitions of
these groups were likely to vary considerably. Physicians at
each site who agreed to participate may not be representa-
tive of all physicians in an area with respect to osteoporosis
recognition and management. We attempted to avoid
altering physician practice by minimizing doctors’ aware-
ness of the study. There were no clinical interventions and
physicians had no involvement in patient recruitment other
than supplying practice lists.
Unlike studies that excluded women because of prior
fracture, diagnosis of osteoporosis, or current treatment for
osteoporosis, GLOWattempted to enlist all women 55 years
and older who were active patients in each physician’s
practice. By doing so, the study will provide a more
complete picture of care received by women in this age
group. Nonetheless, some participation biases are likely. It
is possible that participants will have greater interest in
bone health issues and seek information, screening, and
treatment more actively. We attempted to reduce selection
bias by creating a survey process that imposed low
respondent burden. Participation required no clinic visits
(by not requiring patients to schedule a clinic visit or face-
to-face interview, we avoid requirements that might make
participation difficult for women who are in poor health or
have no or limited access to transportation) and question-
naires were mailed directly to the subject’s home and
typically required only 15–20 min to complete. High
response rates at most sites (median 62%) suggest that this
strategy was successful. Comparison of characteristics for
the sample of US women with those of the nationally
representative sample of comparably aged NHANES
women demonstrated that although GLOW women were
better educated, more likely to be white, and reported better
health, the prevalence of risk factors for fracture was similar.
All data are collected by patient self-report. While this
approach is subject to limitations of recall and recall bias, it
has the advantages of efficiency and methodological
consistency. The combination of mail and telephone
surveys is amenable to collection of data on quality of life,
health status, and fracture risk factors of interest. The
efficiency of the mail and phone survey approach also
makes it feasible to obtain a substantial sample size and to
provide adequate statistical power for the analysis of
fracture outcomes, which are relatively rare events. The
survey format also allows standardized administration that
reduces the issues of noncomparability and variation in data
quality that would arise if medical records and public health
care databases from several different countries were used.
Reports that have examined the validity of self-report of
Osteoporos Int (2009) 20:1107–1116 1113prescription medication use and fractures have shown
reasonable accuracy [31–36]. Self-report may be preferable
to the abstraction from medical records of data on diagnosis
and treatment, given inconsistencies in record keeping
between physicians and between study regions and
countries. Additionally, records from primary care physi-
cians may not include evidence of treatment initiated by a
specialist physician. Validation of self-reports of variables
such as fractures and bone mineral density examinations
may be possible for subsets of subjects in sites where
electronic medical records are available.
Conclusions
GLOW will provide important information on the patterns
of management of fracture risk in older women over a 5-
year period. The collection of data in a similar fashion in
ten countries will allow comparisons of patient experience
with prevention and treatment, and an understanding of
differences in the distribution of risk among older women
on an international basis.
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